Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
All content for Breast Cancer Conversations is the property of SurvivingBreastCancer.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
273. Why One-Size-Fits-All Cancer Care Doesn’t Work
Breast Cancer Conversations
49 minutes
3 weeks ago
273. Why One-Size-Fits-All Cancer Care Doesn’t Work
Love the episode? Send us a text! Today’s episode is going to challenge how you think about treatment. What if cancer care wasn’t one-size-fits-all? What if every decision — from the drugs you take to the supplements you choose — was tailored to your own biology? My guest, Dr. John Oertle, Chief Medical Director at Envita Medical Centers, has spent over 25 years pioneering a truly personalized, integrative approach that merges precision oncology, functional medicine, and technology. We’ll exp...
Breast Cancer Conversations
Love the episode? Send us a text! Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast Cancer In this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what’s new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option. Dr. Layman walks us through the VIKTORIA-1 trial, a phase I...
